Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed / Refractory Mantle Cell Lymphoma

Lymphoma

The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed / refractory mantle cell lymphoma (MCL)
Lymphoma
II
Oluwole, Olalekan
NCT02601313
VICCCTT15116

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML / MDS After HSCT

Multiple Cancer Types

This is a Phase 1, open-label, non-randomized, single and multiple dose escalation study designed to evaluate the safety and preliminary efficacy of administering Mana 312 to subjects with AML / MDS after allogeneic HSCT.
Leukemia, Myelodysplastic Syndrome, Phase I
I
Byrne, Michael
NCT04679194
VICCCTTP20107

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed / Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed / Refractory B-Cell Non-Hodgkin Lymphoma

Pediatric Leukemia

The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed / refractory (r / r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r / r) B-cell non-Hodgkin lymphoma (NHL).
Pediatric Leukemia
I/II
Kitko, Carrie
NCT02625480
VICCPED15143

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid / Round Cell Liposarcoma

Sarcoma

This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1 and Cohort 2) or MRCLS (Cohort 1) .
Sarcoma
II
Keedy, Vicki
NCT04044768
VICCSAR1948

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: